Bacterial and human exonucleases mediate interkingdom antiviral immunity
Santos, C. R.; El-Guindy, A.; Embry, A.; Martin, A. E.; Alto, N. M.; Gammon, D. B.; Forsberg, K. J.
Show abstract
All kingdoms of life have developed strategies to limit viral infection. In humans, interferons induce a suite of antiviral factors that collectively provide immunity. Some human immune genes are homologous with antiphage defense genes in bacteria, though the extent of this overlap is not known. Here, we screened a panel of human innate immune genes for phage defense in Escherichia coli and found that the RNA exonuclease ISG20 potently restricts the RNA phages MS2 and Q{beta}. Purified ISG20 trims the 3-prime untranslated regions (UTRs) of RNA phage genomes, explaining its ability to block phage replication in E. coli. Homologs of ISG20 from bacteria function similarly, exhibiting nuclease-dependent antiphage defense in bacteria and UTR-trimming in vitro. When expressed in human cells, these bacterial exonucleases also restrict human RNA viruses with similar potency as the human antiviral protein ISG20. Thus, antiviral genes from both humans and bacteria can function interchangeably. This bidirectional, interkingdom immunity suggests that viral targets overlap, implying that both bacterial and human factors recognize ancient features of RNA viruses.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- The cut site specificity of the influenza A virus endoribonuclease PA-X allows it to discriminate between host and viral mRNAs 98%
- Ubiquitin-like cGAS chain formation by a super enzyme activates anti-phage response 97%
- Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants 97%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.